LinaThera hat dies direkt geteilt
Delighted to announce the first clinical trial with a 61Cu-based tracer ever. Thanks to the #Nuclidium team, #Pharmalogic and #Dr. Gary Ulaner and the team at #HOAG Family Cancer Institute for the excellent teamwork Stay tuned for more results!
We are excited to announce that the first patient has been imaged in a Phase 1 study evaluating our 61Cu-based radiotracer in patients with PSMA-positive prostate cancer. This is the first candidate from our broad theranostic pipeline to enter the clinic. 61Cu-NuriPro is the diagnostic component of our NuriPro program, binding specifically to Prostate Specific Membrane Antigen (PSMA). Upon successful completion of the trial we will advance our NuriPro program into a Phase 1/2 theranostic clinical trial, evaluating both the 61Cu-based imaging alongside the 67Cu-based therapeutic candidate. The non-randomized study is initiated by Gary Ulaner and is being conducted at Hoag Memorial Hospital Presbyterian in Newport Beach, California. It will evaluate the safety and effectiveness of our candidate compared to an 18F-based, FDA-approved PSMA-targeting radiotracer. 61Cu-NuriPro has the potential to overcome both detection and production challenges of currently available agents. It enables delayed imaging, allowing for the detection of even the smallest metastases. With a 3.3-hour half-life, compared to the 1-to-2-hour half-life of most molecular imaging agents, it allows for a far greater distribution range following production. In addition, it can be easily manufactured at room temperature, enabling on-demand preparation and a simplified and easy-to-apply workflow with reduced need for laboratory equipment. #CancerCare #CancerDiagnostics #Prostatecancer #MedicalImaging #PrecisionOncology #Radiopharmaceuticals #Radiotheranostics #Theranostics